US EditionBriaCell adds two key clinical sites to Phase 3 study of lead candidate in MBC - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
BriaCell adds two key clinical sites to Phase 3 study of lead candidate in MBC - BioTuesdays
BriaCell Therapeutics (NASDAQ: BCTX, BCTXW, BCTXZ; TSX: BCT) has announced the addition of two major cancer centers to its ongoing pivotal Phase 3 clinical study of Bria-IMT plus immune checkpoint inhibitor versus physician’s choice in advanced metastatic breast cancer (MBC). The additional sites include the Los Angeles Cancer Network and Smilow Cancer Hospital at New Haven—both of which have 15 satellite locations. According to BriaCell, positi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
